Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolera.
Vamorolone maintained muscle strength and function, as well as improved height velocity, compared with glucocorticoid therapy among those with Duchenne muscular dystrophy, according to data published in JAMA Network Open.“Despite scientific advances, the only medications that have consistently demonstrated efficacy in clinical trials for [Duchenne muscular dystrophy (DMD)] are
Duchenne Muscular Dystrophy Market 2021-2026 Dynamics and Outlook | PTC Therapeutics, Sarepta Therapeutics, Bristol-Myers Squibb blackseagrain.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blackseagrain.net Daily Mail and Mail on Sunday newspapers.
Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.